Jade Biosciences Quarterly Income Statement
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.39+0.24 (+1.70%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jade Biosciences revenue and earnings
Jade Biosciences reported a net loss of $55.8 million, compared with a loss of $32.1 million a year earlier. Diluted earnings per share came in at -$0.76.
Summary generated from market data by MetaCap's automated system. Methodology
Jade Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 58.92M | 43.45M | 34.98M | 27.40M | 27.78M | 23.38M | 6.40M | 14.96M | 26.16M | 24.62M | 22.07M | 21.37M |
| Research & Development | 50.06M | 36.05M | 28.54M | 22.01M | 22.55M | 20.02M | 1.53M | 13.58M | 21.25M | 20.08M | 17.81M | 16.88M |
| Operating Income | -58.92M | -43.45M | -34.98M | -27.40M | -27.78M | -23.38M | -6.40M | -14.96M | -26.16M | -24.62M | -22.07M | -21.37M |
| Other Income (Expense) | 3.17M | 3.09M | 3.10M | 2.23M | -4.36M | -14.79M | 1.03M | -1.31M | 1.39M | 1.43M | 1.71M | 1.80M |
| Pretax Income | -55.75M | -40.35M | — | — | -32.13M | -38.17M | — | — | — | — | — | — |
| Income Tax | 15.00K | 16.00K | 58.00K | 0 | 0 | — | 0 | 0 | — | — | — | — |
| Net Income | -55.77M | -40.37M | -31.93M | -25.18M | -32.13M | -38.17M | -5.43M | -16.28M | -24.77M | -23.19M | -20.41M | -19.56M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.76 | -0.57 | 10.25 | -0.48 | -0.86 | -12.10 | 4.41 | -5.16 | -0.86 | -0.83 | -0.73 | -0.71 |
| EPS (Diluted) | -0.76 | -0.57 | 10.25 | -0.48 | -0.86 | -12.10 | 4.41 | -5.16 | -0.86 | -0.83 | -0.73 | -0.71 |
| Shares Outstanding (Basic) | 61.05M | 57.78M | — | 39.58M | 28.43M | 3.16M | — | 3.16M | 28.76M | 27.80M | — | 27.64M |
| Shares Outstanding (Diluted) | 61.05M | 57.78M | — | 39.58M | 28.43M | 3.16M | — | 3.16M | 28.76M | 27.80M | — | 27.64M |
| EBITDA | -58.91M | -43.44M | -34.97M | -27.39M | -27.78M | -23.38M | -6.39M | -14.75M | -26.14M | -24.59M | -22.04M | -21.34M |
This table shows 12 quarterly periods of Jade Biosciences's income statement, from Q2 2026 back to Q3 2023, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow JBIO's reporting calendar. What is a income statement?